Global Nasopharyngeal Cancer Market
Global Nasopharyngeal Cancer Market

Nasopharyngeal Cancer Comprehensive Study by Type (Keratinizing Squamous Cell Carcinoma, Nonkeratinizing Squamous Cell Carcinoma, Undifferentiated or Poorly Differentiated), Application (Hospitals, Clinics, Cancer Treatment and Rehabilitation Centers), Treatment (Surgery, Radiation (External Radiation Therapy) Players and Region - Global Market Outlook to 2025

Nasopharyngeal Cancer Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 230 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Nasopharyngeal Cancer Market Scope
Nasopharyngeal cancer is a disease in which malignant (cancer) cells form in the tissues of the nasopharynx. The nasopharynx is the upper part of the pharynx (throat) behind the nose. The nasopharynx is located at the base of the skull, above the roof of the mouth. It is the opening of the nostrils. The increasing geriatric population, rise in consumption of tobacco, increasing health awareness, changing lifestyle, are key driving factors for the nasopharyngeal cancer treatment market.

The Nasopharyngeal Cancer market study is segmented by Type (Keratinizing Squamous Cell Carcinoma, Nonkeratinizing Squamous Cell Carcinoma and Undifferentiated or Poorly Differentiated), by Application (Hospitals, Clinics and Cancer Treatment and Rehabilitation Centers) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Nasopharyngeal Cancer market throughout the predicted period.

Sanofi (France), F. Hoffmann-La Roche (Switzerland), Merck & Co. (United States), Cyclacel Pharmaceuticals (United States), Celgene (United States), BioDiem (Canada), Biocon Limited (India), Bristol Myers Squibb (United States) and GlaxoSmithKline Plc (United Kingdom) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Nasopharyngeal Cancer market by Type, Application and Region.

On the basis of geography, the market of Nasopharyngeal Cancer has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In Aug 2019, Pfizer Inc. announced the closing of its joint venture with GlaxoSmithKline plc to combine the parties’ respective consumer healthcare businesses to create the world’s largest over-the-counter (OTC) business with robust iconic brands.
In May 2020, A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumours caused by the virus. It is the first known agent to successfully target the virus and disturb its latency in tumor cells in this way. and In June 2019, BeiGene, Ltd. today announced preliminary results of tislelizumab, its investigational anti-PD-1 inhibitor, in Chinese patients with nasopharyngeal cancer (NPC) that were presented in a poster at the 2019 American Society of Clinical Oncology (ASCO)


Market Trend
  • Surging Clinical Trials for New Nasopharyngeal Cancer Drug

Market Drivers
  • Rising Burden of the Cancer Disease
  • Growing Awareness Towards Diagnosis and Treatment

Opportunities
  • Increasing Healthcare Awareness
  • Rising Spending on Healthcare Technologies in Developing Regions

Restraints
  • High Cost of the Treatment

Challenges
  • Side Effects Associated with the Disease


Key Target Audience
Nasopharyngeal Cancer Drug Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Keratinizing Squamous Cell Carcinoma
  • Nonkeratinizing Squamous Cell Carcinoma
  • Undifferentiated or Poorly Differentiated
By Application
  • Hospitals
  • Clinics
  • Cancer Treatment and Rehabilitation Centers
By Treatment
  • Surgery
  • Radiation (External Radiation Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Burden of the Cancer Disease
      • 3.2.2. Growing Awareness Towards Diagnosis and Treatment
    • 3.3. Market Challenges
      • 3.3.1. Side Effects Associated with the Disease
    • 3.4. Market Trends
      • 3.4.1. Surging Clinical Trials for New Nasopharyngeal Cancer Drug
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nasopharyngeal Cancer, by Type, Application, Treatment and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Nasopharyngeal Cancer (Value)
      • 5.2.1. Global Nasopharyngeal Cancer by: Type (Value)
        • 5.2.1.1. Keratinizing Squamous Cell Carcinoma
        • 5.2.1.2. Nonkeratinizing Squamous Cell Carcinoma
        • 5.2.1.3. Undifferentiated or Poorly Differentiated
      • 5.2.2. Global Nasopharyngeal Cancer by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Cancer Treatment and Rehabilitation Centers
      • 5.2.3. Global Nasopharyngeal Cancer by: Treatment (Value)
        • 5.2.3.1. Surgery
        • 5.2.3.2. Radiation (External Radiation Therapy
      • 5.2.4. Global Nasopharyngeal Cancer Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Nasopharyngeal Cancer: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cyclacel Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Celgene (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioDiem (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Biocon Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol Myers Squibb (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Nasopharyngeal Cancer Sale, by Type, Application, Treatment and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Nasopharyngeal Cancer (Value)
      • 7.2.1. Global Nasopharyngeal Cancer by: Type (Value)
        • 7.2.1.1. Keratinizing Squamous Cell Carcinoma
        • 7.2.1.2. Nonkeratinizing Squamous Cell Carcinoma
        • 7.2.1.3. Undifferentiated or Poorly Differentiated
      • 7.2.2. Global Nasopharyngeal Cancer by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Cancer Treatment and Rehabilitation Centers
      • 7.2.3. Global Nasopharyngeal Cancer by: Treatment (Value)
        • 7.2.3.1. Surgery
        • 7.2.3.2. Radiation (External Radiation Therapy
      • 7.2.4. Global Nasopharyngeal Cancer Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nasopharyngeal Cancer: by Type(USD Million)
  • Table 2. Nasopharyngeal Cancer Keratinizing Squamous Cell Carcinoma , by Region USD Million (2014-2019)
  • Table 3. Nasopharyngeal Cancer Nonkeratinizing Squamous Cell Carcinoma , by Region USD Million (2014-2019)
  • Table 4. Nasopharyngeal Cancer Undifferentiated or Poorly Differentiated , by Region USD Million (2014-2019)
  • Table 5. Nasopharyngeal Cancer: by Application(USD Million)
  • Table 6. Nasopharyngeal Cancer Hospitals , by Region USD Million (2014-2019)
  • Table 7. Nasopharyngeal Cancer Clinics , by Region USD Million (2014-2019)
  • Table 8. Nasopharyngeal Cancer Cancer Treatment and Rehabilitation Centers , by Region USD Million (2014-2019)
  • Table 9. Nasopharyngeal Cancer: by Treatment(USD Million)
  • Table 10. Nasopharyngeal Cancer Surgery , by Region USD Million (2014-2019)
  • Table 11. Nasopharyngeal Cancer Radiation (External Radiation Therapy , by Region USD Million (2014-2019)
  • Table 12. South America Nasopharyngeal Cancer, by Country USD Million (2014-2019)
  • Table 13. South America Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 14. South America Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 15. South America Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 16. Brazil Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 17. Brazil Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 18. Brazil Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 19. Argentina Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 20. Argentina Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 21. Argentina Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 22. Rest of South America Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 23. Rest of South America Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 24. Rest of South America Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 25. Asia Pacific Nasopharyngeal Cancer, by Country USD Million (2014-2019)
  • Table 26. Asia Pacific Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 27. Asia Pacific Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 28. Asia Pacific Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 29. China Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 30. China Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 31. China Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 32. Japan Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 33. Japan Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 34. Japan Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 35. India Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 36. India Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 37. India Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 38. South Korea Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 39. South Korea Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 40. South Korea Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 41. Taiwan Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 42. Taiwan Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 43. Taiwan Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 44. Australia Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 45. Australia Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 46. Australia Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 47. Rest of Asia-Pacific Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 50. Europe Nasopharyngeal Cancer, by Country USD Million (2014-2019)
  • Table 51. Europe Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 52. Europe Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 53. Europe Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 54. Germany Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 55. Germany Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 56. Germany Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 57. France Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 58. France Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 59. France Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 60. Italy Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 61. Italy Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 62. Italy Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 63. United Kingdom Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 64. United Kingdom Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 65. United Kingdom Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 66. Netherlands Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 67. Netherlands Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 68. Netherlands Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 69. Rest of Europe Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 70. Rest of Europe Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 71. Rest of Europe Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 72. MEA Nasopharyngeal Cancer, by Country USD Million (2014-2019)
  • Table 73. MEA Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 74. MEA Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 75. MEA Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 76. Middle East Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 77. Middle East Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 78. Middle East Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 79. Africa Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 80. Africa Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 81. Africa Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 82. North America Nasopharyngeal Cancer, by Country USD Million (2014-2019)
  • Table 83. North America Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 84. North America Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 85. North America Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 86. United States Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 87. United States Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 88. United States Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 89. Canada Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 90. Canada Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 91. Canada Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 92. Mexico Nasopharyngeal Cancer, by Type USD Million (2014-2019)
  • Table 93. Mexico Nasopharyngeal Cancer, by Application USD Million (2014-2019)
  • Table 94. Mexico Nasopharyngeal Cancer, by Treatment USD Million (2014-2019)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Nasopharyngeal Cancer: by Type(USD Million)
  • Table 105. Nasopharyngeal Cancer Keratinizing Squamous Cell Carcinoma , by Region USD Million (2020-2025)
  • Table 106. Nasopharyngeal Cancer Nonkeratinizing Squamous Cell Carcinoma , by Region USD Million (2020-2025)
  • Table 107. Nasopharyngeal Cancer Undifferentiated or Poorly Differentiated , by Region USD Million (2020-2025)
  • Table 108. Nasopharyngeal Cancer: by Application(USD Million)
  • Table 109. Nasopharyngeal Cancer Hospitals , by Region USD Million (2020-2025)
  • Table 110. Nasopharyngeal Cancer Clinics , by Region USD Million (2020-2025)
  • Table 111. Nasopharyngeal Cancer Cancer Treatment and Rehabilitation Centers , by Region USD Million (2020-2025)
  • Table 112. Nasopharyngeal Cancer: by Treatment(USD Million)
  • Table 113. Nasopharyngeal Cancer Surgery , by Region USD Million (2020-2025)
  • Table 114. Nasopharyngeal Cancer Radiation (External Radiation Therapy , by Region USD Million (2020-2025)
  • Table 115. South America Nasopharyngeal Cancer, by Country USD Million (2020-2025)
  • Table 116. South America Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 117. South America Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 118. South America Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 119. Brazil Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 120. Brazil Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 121. Brazil Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 122. Argentina Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 123. Argentina Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 124. Argentina Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 125. Rest of South America Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 126. Rest of South America Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 127. Rest of South America Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 128. Asia Pacific Nasopharyngeal Cancer, by Country USD Million (2020-2025)
  • Table 129. Asia Pacific Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 130. Asia Pacific Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 131. Asia Pacific Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 132. China Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 133. China Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 134. China Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 135. Japan Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 136. Japan Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 137. Japan Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 138. India Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 139. India Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 140. India Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 141. South Korea Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 142. South Korea Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 143. South Korea Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 144. Taiwan Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 145. Taiwan Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 146. Taiwan Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 147. Australia Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 148. Australia Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 149. Australia Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 150. Rest of Asia-Pacific Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 151. Rest of Asia-Pacific Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 152. Rest of Asia-Pacific Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 153. Europe Nasopharyngeal Cancer, by Country USD Million (2020-2025)
  • Table 154. Europe Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 155. Europe Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 156. Europe Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 157. Germany Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 158. Germany Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 159. Germany Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 160. France Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 161. France Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 162. France Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 163. Italy Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 164. Italy Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 165. Italy Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 166. United Kingdom Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 167. United Kingdom Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 168. United Kingdom Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 169. Netherlands Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 170. Netherlands Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 171. Netherlands Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 172. Rest of Europe Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 173. Rest of Europe Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 174. Rest of Europe Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 175. MEA Nasopharyngeal Cancer, by Country USD Million (2020-2025)
  • Table 176. MEA Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 177. MEA Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 178. MEA Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 179. Middle East Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 180. Middle East Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 181. Middle East Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 182. Africa Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 183. Africa Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 184. Africa Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 185. North America Nasopharyngeal Cancer, by Country USD Million (2020-2025)
  • Table 186. North America Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 187. North America Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 188. North America Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 189. United States Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 190. United States Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 191. United States Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 192. Canada Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 193. Canada Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 194. Canada Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 195. Mexico Nasopharyngeal Cancer, by Type USD Million (2020-2025)
  • Table 196. Mexico Nasopharyngeal Cancer, by Application USD Million (2020-2025)
  • Table 197. Mexico Nasopharyngeal Cancer, by Treatment USD Million (2020-2025)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nasopharyngeal Cancer: by Type USD Million (2014-2019)
  • Figure 5. Global Nasopharyngeal Cancer: by Application USD Million (2014-2019)
  • Figure 6. Global Nasopharyngeal Cancer: by Treatment USD Million (2014-2019)
  • Figure 7. South America Nasopharyngeal Cancer Share (%), by Country
  • Figure 8. Asia Pacific Nasopharyngeal Cancer Share (%), by Country
  • Figure 9. Europe Nasopharyngeal Cancer Share (%), by Country
  • Figure 10. MEA Nasopharyngeal Cancer Share (%), by Country
  • Figure 11. North America Nasopharyngeal Cancer Share (%), by Country
  • Figure 12. Global Nasopharyngeal Cancer share by Players 2019 (%)
  • Figure 13. Global Nasopharyngeal Cancer share by Players (Top 3) 2019(%)
  • Figure 14. Global Nasopharyngeal Cancer share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 17. Sanofi (France) Revenue: by Geography 2019
  • Figure 18. F. Hoffmann-La Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. F. Hoffmann-La Roche (Switzerland) Revenue: by Geography 2019
  • Figure 20. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Merck & Co. (United States) Revenue: by Geography 2019
  • Figure 22. Cyclacel Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cyclacel Pharmaceuticals (United States) Revenue: by Geography 2019
  • Figure 24. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 25. Celgene (United States) Revenue: by Geography 2019
  • Figure 26. BioDiem (Canada) Revenue, Net Income and Gross profit
  • Figure 27. BioDiem (Canada) Revenue: by Geography 2019
  • Figure 28. Biocon Limited (India) Revenue, Net Income and Gross profit
  • Figure 29. Biocon Limited (India) Revenue: by Geography 2019
  • Figure 30. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 31. Bristol Myers Squibb (United States) Revenue: by Geography 2019
  • Figure 32. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2019
  • Figure 34. Global Nasopharyngeal Cancer: by Type USD Million (2020-2025)
  • Figure 35. Global Nasopharyngeal Cancer: by Application USD Million (2020-2025)
  • Figure 36. Global Nasopharyngeal Cancer: by Treatment USD Million (2020-2025)
  • Figure 37. South America Nasopharyngeal Cancer Share (%), by Country
  • Figure 38. Asia Pacific Nasopharyngeal Cancer Share (%), by Country
  • Figure 39. Europe Nasopharyngeal Cancer Share (%), by Country
  • Figure 40. MEA Nasopharyngeal Cancer Share (%), by Country
  • Figure 41. North America Nasopharyngeal Cancer Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Sanofi (France)
  • F. Hoffmann-La Roche (Switzerland)
  • Merck & Co. (United States)
  • Cyclacel Pharmaceuticals (United States)
  • Celgene (United States)
  • BioDiem (Canada)
  • Biocon Limited (India)
  • Bristol Myers Squibb (United States)
  • GlaxoSmithKline Plc (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation